Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

CJC/IPA Protocol Overview, Dosing & Safety | Peptide Database

CJC/IPA Protocol (CJC-1295/Ipamorelin) GHRH/GHRP Combination | Growth Hormone Optimization Community Research Join others researching CJC/IPA Protocol — share findings, ask questions, and learn from real experiences A dual-pathway protocol combining CJC-1295 a

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

CJC/IPA Protocol (CJC-1295/Ipamorelin)

GHRH/GHRP Combination | Growth Hormone Optimization

Community Research

Join others researching CJC/IPA Protocol — share findings, ask questions, and learn from real experiences

A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.

CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.

Molecular Data

Complex or non-standard sequence format

Research Indications

Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training.

Sustained GH patterns may accelerate muscle repair between exercise sessions.

GH optimization helps maintain muscle during caloric restriction or aging.

Growth hormone promotes lipolysis while supporting lean tissue maintenance.

Enhanced GH patterns may improve glucose and fat utilization.

Evening GH peaks align with deeper, more restorative sleep patterns.

Sustained GH elevation supports skin elasticity and connective tissue health.

Growth hormone supports tissue repair and recovery from exercise or injury.

Enhanced collagen synthesis supports joint and connective tissue integrity.

Dosing Protocols

Subcutaneous administration optimal for bioavailability; available as blended vials or separate formulations.

General Health Optimization

200mcg each (0.2mL if 1mg/mL)

Once daily

SubQ

Performance Enhancement

250mcg each (0.25mL if 1mg/mL)

Recovery Optimization

300mcg each (0.3mL if 1mg/mL)

Conservative Approach

150mcg each (0.15mL if 1mg/mL)

5 days per week

Reconstitution Instructions

Bacteriostatic water (2-4mL)

Insulin syringes (0.3-1mL capacity)

Alcohol swabs for sterilization

1 BLENDED: Add 2mL bacteriostatic water to create ~2mg/mL concentration

2 SEPARATE: Add 2mL water to each vial for 1mg/mL per peptide

3 Draw 0.2-0.3mL for 200-300mcg dosing

4 Mix equal volumes or inject at different sites

5 Administer 2-3 hours post-meal, 30-60 minutes before bed

6 Rotate subcutaneous sites (abdomen, thigh, upper arm) daily

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Water retention and joint swelling

Carpal tunnel syndrome (numbness/tingling)

Mild blood glucose elevation

Injection site irritation with improper rotation

Stop Signs - Discontinue if:

Persistent joint pain or swelling indicating fluid retention

Significant blood glucose changes or diabetic control issues

Unusual fatigue, lethargy, or mood deterioration

Injection site infections or persistent reactions

Numbness or tingling in hands/feet

Signs of accelerated tumor growth if cancer history exists

Contraindications

Cancer history or active malignancy

Severe diabetes requiring tight glucose control

Carpal tunnel syndrome or nerve compression disorders

Quality Checklist

Good Signs

Standard format labeling: '10mg total: 5mg CJC-1295 + 5mg Ipamorelin'

1:1 ratio maintenance between peptides for optimal effects

Clear reconstitution without particles or cloudiness

Certificate of Analysis with individual peptide purities

Proper cold chain with cold packs and immediate refrigeration

Warning Signs

Format selection: Beginners prefer separate vials for tolerance testing

Blended format offers convenience but limits dose adjustment

Combination protocols lack peer-reviewed clinical validation

Bad Signs

Damaged packaging or missing refrigeration

Heat exposure during shipping

Lack of Certificate of Analysis documentation

Frequently Asked Questions

Why do people combine CJC-1295 and Ipamorelin instead of using them separately?

CJC-1295 and Ipamorelin target GH secretion through complementary mechanisms—CJC-1295 activates GHRH receptors while Ipamorelin activates ghrelin receptors—creating synergistic effects greater than either peptide alone. Ipamorelin uniquely avoids cortisol elevation, making the combination particularly effective and tolerable.

Can I use the CJC/IPA protocol if I have a history of diabetes?

CJC/IPA combinations require caution with diabetes history due to GH's insulin-antagonistic effects. Both peptides elevate growth hormone which can impair glucose tolerance. Medical supervision and regular blood glucose monitoring are essential before starting, especially with the continuous GH elevation this protocol provides.

What's the advantage of Ipamorelin over GHRP-6 in this combination?

Ipamorelin is selective for GH release and does NOT elevate cortisol or prolactin even at high doses, whereas GHRP-6 causes significant appetite stimulation and potential cortisol elevation. For the CJC/IPA protocol, Ipamorelin provides cleaner GH stimulation without the side effects of broader GHRP peptides.

Should CJC/IPA be dosed together in the same injection or separately?

Both approaches work—some use blended vials containing both peptides at a 1:1 ratio, while others inject separately at the same or different sites. Blended vials offer convenience but allow less flexibility to adjust individual peptide doses, while separate vials let you customize ratios if needed.

References

Single CJC-1295 injection produced dose-dependent 2-10 fold GH increases for 6+ days and 1.5-3 fold IGF-1 increases for 9-11 days; estimated half-life 5.8-8.1 days.

Ipamorelin is the first GHRP-receptor agonist with selectivity for GH release similar to GHRH; does not release ACTH or cortisol even at doses over 200-fold the ED50 for GH.

CJC-1295 preserves pulsatile GH secretion with unaltered pulse frequency and magnitude; basal GH levels increased 7.5-fold, mean GH 46%, and IGF-1 45%.

GHS potentiate GHRH-induced cAMP in a dose-dependent manner requiring co-expression of both receptors, providing the cellular basis for GHRH/GHRP synergy.

Related Peptides

No known interactions; different mechanisms (GH optimization vs. tissue repair signaling).

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Community Research

Join others researching Pitavastatin — share findings, ask questions, and learn from real experiences Pitavastatin is a newer-generation synthetic statin approved by the FDA in 2009 under the brand name Livalo. It distinguishes itself from other statins through its minimal cytochrome P450 metabolism, which translates to significantly fewer drug-drug interactions than atorvastatin, simvastatin, or lovastatin. This characteristic makes pitavastatin particularly attractive for individuals taking multiple medications or compounds simultaneously, a situation common among anabolic steroid users who may be running ancillaries, aromatase inhibitors, and other support compounds alongside their cycles. Unlike most statins that are heavily metabolized by CYP3A4 or CYP2C9, pitavastatin is primarily metabolized via glucuronidation by UGT1A3 and UGT2B7, with negligible involvement of CYP enzymes. This means compounds and medications that inhibit or induce CYP3A4 do not meaningfully alter pitavastatin blood levels. Clinically, pitavastatin delivers LDL reductions of 38-45% at its standard 2-4 mg dose range, placing it in the moderate-to-high intensity category. Perhaps most notably, pitavastatin carries the lowest risk of new-onset diabetes among all statins, a finding consistently demonstrated across multiple clinical trials and meta-analyses including the LIVES study and J-PREDICT trial. This makes it an especially prudent choice for individuals with pre-existing insulin resistance or those using compounds known to impact glucose metabolism. Pitavastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway responsible for cholesterol biosynthesis in the liver. By blocking this enzyme, pitavastatin reduces intracellular cholesterol concentration in hepatocytes, triggering compensatory upregulation of LDL receptor expression on the hepatocyte surface. The increased LDL receptor density enhances the clearance of circulating LDL cholesterol, VLDL remnants, and IDL particles from the bloodstream. Pitavastatin has high binding affinity for HMG-CoA reductase and demonstrates potent LDL-lowering efficacy relative to its low milligram dosing. Beyond direct lipid lowering, pitavastatin exerts pleiotropic cardiovascular effects: it improves endothelial function by enhancing nitric oxide production, reduces vascular inflammation and oxidative stress, and stabilizes atherosclerotic plaques. Uniquely among statins, pitavastatin has been shown to raise HDL cholesterol more robustly than other agents in the class, with increases of 5-15% commonly observed. This HDL-raising effect is thought to involve upregulation of apolipoprotein A-I synthesis and enhanced reverse cholesterol transport. In the context of AAS use, pitavastatin addresses the classic androgen-induced dyslipidemia pattern of elevated LDL and suppressed HDL, with its relatively stronger HDL-raising capacity being an advantage over other statins when HDL suppression is a primary concern.

Source: peptide-db.com ↗

Research Indications

Rapid improvement in sustained attention, working memory, and mental clarity within 15-30 minutes. Enhances both short-term and long-term memory consolidation through BDNF upregulation. Significant improvement in cognitive performance during mental fatigue, with lasting effects. Accelerates functional recovery through enhanced neuroplasticity and BDNF elevation. Protects against neural oxidative damage and supports cellular repair mechanisms. Rapidly increases BDNF and TrkB receptor expression, supporting neuronal survival. Improves episodic memory formation and recall through default mode network optimization. Enhances acquisition of new information through improved synaptic plasticity.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Ketoconazole for hair loss is used exclusively as a medicated shampoo, available in 1% (OTC) and 2% (prescription) concentrations. The shampoo is lathered into the scalp and left on for approximately 5 minutes before rinsing, applied 2-3 times per week. This contact time allows adequate absorption into the scalp tissue while minimizing systemic exposure. For hair loss purposes, the 2% prescription formulation is generally preferred, though the 1% OTC version (Nizoral A-D) has also shown benefit in studies. Hair loss adjunct therapy (standard) 2% shampoo 2-3x per week, leave on scalp for 5 minutes Topical (shampoo) Hair loss adjunct therapy (OTC) 1% shampoo Seborrheic dermatitis / dandruff control 1-2% shampoo 2x per week for 4 weeks, then as needed

Source: peptide-db.com ↗
Side effects

Common Side Effects

Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users Metallic taste in mouth Decreased appetite Flatulence and abdominal distension Loose stools, particularly when initiating therapy or increasing dose

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides

01
Peptide Therapy Guide Editorial Team

VIP Overview, Dosing & Safety | Peptide Database

VIP (Vasoactive Intestinal Polypeptide) Vasoactive Intestinal Peptide | Neuropeptide Community Research Join others researching VIP — share findings, ask questions, and learn from real experiences Vasoactive I…

Read guide →
03
Peptide Therapy Guide Editorial Team

Vilon Overview, Dosing & Safety | Peptide Database

Vilon (KE) KE Dipeptide | Thymus Immune Bioregulator Community Research Join others researching Vilon — share findings, ask questions, and learn from real experiences Vilon is a Khavinson bioregulator dipeptid…

Read guide →